The global conjunctivitis treatment market is experiencing significant growth, driven by the increasing prevalence of eye infections, advancements in drug development, and rising awareness about eye health. Conjunctivitis, also known as "pink eye," remains one of the most common eye conditions affecting individuals of all ages worldwide.
According to Fortune Business Insights, the conjunctivitis treatment market was valued at USD 3.85 billion in 2019 and is projected to reach USD 4.38 billion by 2027, exhibiting a CAGR of 3.7% during the forecast period. In 2019, North America dominated the conjunctivitis treatment market with a market share of 48.05%.
In June 2021, Santen Pharmaceutical Co., Ltd. announced that its drug Verkazia received U.S. FDA approval for the treatment of vernal keratoconjunctivitis in both children and adults. This development not only expands Santen’s product line but also offers new therapeutic options for a severe form of conjunctivitis.